Evidence map›Paper›PMID 28817722›Full record

ArticlePloS one2017

Nicotinamide alone accelerates the conversion of mouse embryonic stem cells into mature neuronal populations.

Síle M Griffin, Mark R Pickard, Rowan P Orme, Clive P Hawkins, Adrian C Williams, Rosemary A Fricker

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Nicotinamide and Demographic and Disease transitions: Moderation is Best.International journal of tryptophan research : IJTR · 2019
    Review
  9. Review
  10. Article
  11. The Influence of Nicotinamide on Health and Disease in the Central Nervous System.International journal of tryptophan research : IJTR · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Síle M GriffinKeele Medical School and Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, England, United Kingdom.
Mark R PickardChester Centre for Stress Research, Institute of Medicine, University of Chester, Chester, United Kingdom.
Rowan P OrmeKeele Medical School and Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, England, United Kingdom.
Clive P HawkinsKeele Medical School and Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, England, United Kingdom.
Adrian C WilliamsDepartment of Neurosciences, University of Birmingham, Birmingham, United Kingdom.
Rosemary A FrickerKeele Medical School and Institute for Science and Technology in Medicine, Keele University, Keele, Staffordshire, England, United Kingdom.ORCID http://orcid.org/0000-0001-8768-510X
Keele University · GBRoyal Stoke University Hospital · GBUniversity of Birmingham · GBUniversity of Chester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVitamin B3 has been shown to play an important role during embryogenesis. Specifically, there is growing evidence that nicotinamide, the biologically active form of vitamin B3, plays a critical role as a morphogen in the differentiation of stem cells to mature cell phenotypes, including those of the central nervous system (CNS). Detailed knowledge of the action of small molecules during neuronal differentiation is not only critical for uncovering mechanisms underlying lineage-specification, but also to establish more effective differentiation protocols to obtain clinically relevant cells for regenerative therapies for neurodegenerative conditions such as Huntington's disease (HD). Thus, this study aimed to investigate the potential of nicotinamide to promote the conversion of stem cells to mature CNS neurons.

methodsNicotinamide was applied to differentiating mouse embryonic stem cells (mESC; Sox1GFP knock-in 46C cell line) during their conversion towards a neural fate. Cells were assessed for changes in their proliferation, differentiation and maturation; using immunocytochemistry and morphometric analysis methods.

resultsResults presented indicate that 10 mM nicotinamide, when added at the initial stages of differentiation, promoted accelerated progression of ESCs to a neural lineage in adherent monolayer cultures. By 14 days in vitro (DIV), early exposure to nicotinamide was shown to increase the numbers of differentiated βIII-tubulin-positive neurons. Nicotinamide decreased the proportion of pluripotent stem cells, concomitantly increasing numbers of neural progenitors at 4 DIV. These progenitors then underwent rapid conversion to neurons, observed by a reduction in Sox 1 expression and decreased numbers of neural progenitors in the cultures at 14 DIV. Furthermore, GABAergic neurons generated in the presence of nicotinamide showed increased maturity and complexity of neurites at 14 DIV. Therefore, addition of nicotinamide alone caused an accelerated passage of pluripotent cells through lineage specification and further to non-dividing mature neurons.

conclusionsOur results show that, within an optimal dose range, nicotinamide is able to singly and selectively direct the conversion of embryonic stem cells to mature neurons, and therefore may be a critical factor for normal brain development, thus supporting previous evidence of the fundamental role of vitamins and their metabolites during early CNS development. In addition, nicotinamide may offer a simple effective supplement to enhance the conversion of stem cells to clinically relevant neurons.

Indexed as

AnimalsCell DifferentiationCell LineageCell ProliferationEmbryonic Stem CellsGreen Fluorescent ProteinsMiceNiacinamideGreen Fluorescent ProteinsNiacinamide

Identifiers

PMID28817722
PMCPMC5560552
OpenAlexW2746333576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.